MethylGene To Resume Development Of Its HDAC Inhibitor, MGCD0103 (Mocetinostat)

MethylGene Inc. (TSX:MYG), announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on MGCD0103, the Company's proprietary selective histone deacetylase (HDAC) inhibitor for cancer. New patient enrollment in the refractory follicular lymphoma cohort of the Company's ongoing Phase II clinical trial (Trial 008) is expected to resume as soon as possible.